🔥 Friday 29 August 2025 Fri, 29 Aug 2025

PYC Therapeutics has reported promising safety data from the initial phase of its clinical trial for PYC-003, an RNA therapy targeting the root cause of Polycystic Kidney Disease. The findings, presented at the ANZSN conference, highlight the drug’s tolerability in healthy volunteers, paving the way for further clinical development.

Virgin Australia has reported a robust FY25 performance, surpassing IPO forecasts with strong earnings growth and operational improvements. The airline reaffirms its positive outlook for FY26, underpinned by fleet expansion and ongoing transformation benefits.

PARKD Limited reported a remarkable 218% increase in revenue to $11.83 million for FY25, driven by key construction projects and new licensing agreements. The company narrowed its loss by 74%, signaling progress in commercialising its modular construction technology.

Jatcorp Limited reported a $6.9 million net loss for FY25, hit by a trademark dispute in China that suspended key product sales. Despite setbacks, the company is accelerating new channel growth and product innovation to regain momentum.

Vection Technologies reports its first positive underlying EBITDA alongside a 22% pro-forma revenue increase, driven by major defence contracts and AI integration. The company’s strategic acquisition and sector diversification set the stage for sustainable growth in FY26.

Virgin Australia reported a 3% revenue increase and a 28% rise in underlying EBIT for FY25, while statutory net profit fell 12% due to IPO and Qatar Airways transaction costs. The airline expanded its fleet and loyalty program amid ongoing transformation efforts.

Tesoro Gold’s latest metallurgical testwork at the Ternera Gold Deposit reveals over 95% gold recovery using a simple, low-cost cyanide process, reinforcing the project’s economic potential and sustainable water use.

Mesoblast Limited marked a transformative year with FDA approval and commercial launch of Ryoncil, its first mesenchymal stromal cell therapy, driving a 191% jump in cell therapy revenues. The company is now poised to expand its footprint in inflammatory diseases with multiple clinical trials and label extensions underway.

PainChek Limited reported a 24% revenue increase to $4.8 million for FY25, narrowing its net loss by 7%, while progressing toward FDA clearance for its Adult PainChek App in the US and launching its Infant App in Australia.

Mesoblast reports a strong FY2025 financial performance driven by the commercial launch of Ryoncil, the first FDA-approved mesenchymal stromal cell therapy for steroid-refractory acute graft-versus-host disease in children. The company is advancing multiple clinical programs targeting inflammatory diseases, heart failure, and chronic low back pain.

Bapcor Limited reported a 117% jump in statutory net profit after tax for FY25, driven by lower significant items despite a slight revenue decline. The company’s strategic reset, including store consolidations and IT upgrades, sets the stage for renewed growth.

Mesoblast Limited has reported its FY2025 results, highlighting the FDA approval and US commercial launch of Ryoncil, its first mesenchymal stromal cell therapy, alongside a $102.1 million net loss and $161.6 million in cash reserves.

NobleOak Life Limited reported robust FY25 results, with a 20% increase in in-force premiums and a 22% rise in underlying NPAT, underpinned by strategic investments in AI and a transition to a capital-efficient Life Company structure.

Bapcor Limited reported a decline in FY25 pro-forma net profit after tax by 8.4%, alongside a successful $170 million debt refinancing extending maturities to 2029-2031. The company declared a fully franked final dividend and announced significant board and executive changes.

NobleOak Life Limited reported a robust 20% growth in in-force premiums and a 22% rise in underlying profit for FY25, surpassing guidance and setting a clear path to $1 billion in-force premium. Strategic partnerships, acquisitions, and product innovation underpin its strong outlook for FY26.

NobleOak Life Limited reported a robust 22% increase in underlying net profit after tax for FY25, driven by strong premium growth and expanding market share. Despite a statutory profit dip due to one-off costs, the insurer plans to reinvest cash flows to fuel future growth and transition to a Life Company structure.

PEXA Group delivered a solid FY25 with 16% revenue growth and a 21% rise in EBITDA, while preparing for a UK platform launch backed by NatWest. Despite statutory losses from impairments, the company strengthened its balance sheet and outlined a confident FY26 outlook.

PEXA Group Ltd reported a robust FY25 with 16% revenue growth and a 21% rise in EBITDA, driven by national expansion and operational efficiencies. The company is advancing its UK platform launch backed by NatWest, while FY26 guidance signals continued growth and strategic focus on AI and resilience.

PEXA Group Limited reported a 16% revenue increase to $393.6 million for FY25, driven by growth across its Australian Exchange, UK International business, and Digital Solutions segments. Despite a statutory net loss of $76.1 million due to impairments and deferred tax derecognition, core EBITDA rose 21% with improved margins.

Asian Battery Metals advances its Oval Cu-Ni-PGE project in Mongolia with significant down-dip extensions confirmed and new electromagnetic targets identified, setting the stage for an active Phase 4 drilling campaign.

Metro Mining has delivered a striking half-year turnaround with a $119.8 million net profit, driven by record shipments, strong pricing, and significant foreign currency hedging gains.

Sumitomo Corporation has committed to a strategic equity investment in Mitchell Services’ Loop Decarbonisation JV, valuing the business at $24 million and signaling confidence in its mining sector emissions solutions.

Bhagwan Marine Limited has delivered a strong first year as an ASX-listed company with record net revenue and EBITDA growth, alongside its inaugural dividend declaration. The company is advancing growth in offshore energy, subsea, ports, and defence sectors while investing in innovation and fleet expansion.

Metro Mining Limited delivered a remarkable turnaround in the first half of 2025, posting record bauxite shipments and a $119.8 million net profit after tax, reversing prior losses and impairments.